Interviews

The FINEARTS-HF late-breaking data were forefront at the 2024 European Society of Cardiology Congress in London.

Neil Goldfarb, president and chief executive officer of the Greater Philadelphia Business Coalition on Health (GPBCH), previews the variety of themes and sessions at the upcoming GPBCH Annual Wellness Summit taking place September 10, 2024.

Manisha Jhamb, MD, MPH, of the University of Pittsburgh Medical Center (UPMC), is excited about CMS's negotiated drug prices under the Inflation Reduction Act (IRA) for patients with kidney disease; conversely, she highlights the challenge of low kidney disease awareness.

Martin Kolb, MD, PhD, professor of medicine at McMaster University, previews key topics to be presented at this year's European Respiratory Society (ERS) Congress.

Steve Pickette, PharmD, BCPS, explains that artificial intelligence (AI)–driven formulary analysis can significantly enhance the efficiency and accuracy of drug selection processes by rapidly compiling and analyzing evidence.

Joseph Biggio, MD, system chair and service line leader for women's services and system chair for maternal fetal medicine at Ochsner Health, discusses some of the innovations to manage hypertension during pregnancy and postpartum.

Ty J. Gluckman, MD, FACC, FAHA, of Providence St. Joseph Health, reacted positively to CMS' drug price cuts under the Inflation Reduction Act, but he also expressed concerns about the potential future impact on drug innovation.

JT Lew, PharmD, MBA, highlights that the primary challenges for patients with multiple sclerosis (MS) in accessing prescribed medications include dealing with the shock of the diagnosis, navigating complex health plan benefits and out-of-pocket costs, and experiencing delays due to insurance barriers.

September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In this first episode, we speak with Michael Lynch, MD, associate professor of emergency medicine at the University of Pittsburgh and an attending emergency physician and medical toxicologist at the University of Pittsburgh Medical Center.

"Now we can actually focus and look at the disease itself, treat the heart disease itself, which is the plaque in the coronary arteries, as opposed to treating the risk of disease," Amir Ahmadi, MD, Mount Sinai, says in an interview at the European Society for Cardiology Congress.

Deepak Bhatt, MD, Mount Sinai Heart, highlights the kidney-specific outcomes of the pivotal EMPACT-MI clinical trial in an interview at the 2024 European Society of Cardiology Congress.

In patients with heart failure with mildly reduced and preserved ejection fraction, finerenone reduced the risk of heart failure worsening or hospitalizations compared with placebo, explained John McMurray, MD, the co–principal investigator of the FINEARTS-HF trial.

At the 25th International AIDS Conference, Emmanuel Nazaire Essam, MD, MPH, presented the analysis, "Medicaid Insurance Expansion and Its Association With HIV Outcomes in Nebraska, USA: An Observational Prospective Cohort Study."

Christopher Kramer, MD, vice president of the American College of Cardiology, discusses the newest data on finerenone for heart failure presented during the FINEARTS Hot Line session at the European Society of Cardiology Congress.

Anna Mueller, MD, and Amir Ahmadi, MD, of Mount Sinai, highlight gaps in risk assessment tools for acute coronary syndrome, calling for more comprehensive screening strategies.

“It's not unusual for complex disorders to have combination therapies,” says Martin Kolb, MD, PhD, professor of medicine at McMaster University.

Advances in technology have made active surveillance in men with prostate cancer possible and prevented treatment for men who don’t need it, said Matthew Nielsen, MD, FACS, chair, Department of Urology, University of North Carolina School of Medicine.

After moderating an emerging science session on acute ST-elevation myocardial infarction care, Dipti Itchhaporia, MD, American College of Cardiology, discussed the growing inclusivity in clinical trials through innovative digital tools and addressed the impact of GLP-1 therapies on cardiovascular treatment.

Jason Romancik, MD, a board-certified hematologist at Emory Winship Cancer Institute, discusses the current treatment landscape in aggressive lymphoma and drivers of high care costs.

Mark Bleackley, PhD, Incannex, discusses the notable and surprising observations from the ongoing RePOSA study, and the developmental challenges they have encountered with their cannabinoid pharmacotherapy for patients with obstructive sleep apnea.

Martin Kolb, MD, PhD, highlights the importance of taking time to explain the complexities of idiopathic pulmonary fibrosis (IPF) to patients before starting long-term treatment.

This newest approval for amivantamab is the second approval in 6 months for the EGFR and MET bispecific antibody.

In part 1 of our interview with Leland Metheny, MD, he explained how a new triple-target chimeric antigen receptor (CAR) T-cell therapy works in multiple myeloma.

While it can seem overwhelming or difficult to decide where to start addressing racial and ethnic disparities in health care, the key is to focus on a manageable area that can be built upon.

Not all patients will want to take triplet therapy, but those with high-volume prostate cancer who are chemotherapy eligible are usually a good fit, explained Neal D. Shore, MD, FACS.

The disease-modifying treatment landscape has expanded in recent years, but access to the latest approved Duchenne muscular dystrophy (DMD) treatments can be a challenge for patients and providers, Aravindhan Veerapandiyan, MD, a pediatric neuromuscular specialist at Arkansas Children’s Hospital, said.

In this interview, Sarah Manes, Global Liver Institute, explores the unique challenges faced by LGBTQI+ individuals, particularly those with disabilities, in accessing and receiving appropriate liver care.

Katherine Baker, MD, MMHC, of Tennessee Oncology, highlights the need for physician-payer collaboration to tackle challenges and drive innovation in specialty care.

Fahad Tahir, MAS, MBA, FACHE, of Ascension St Thomas, discusses health system innovation and entrepreneurship, highlighting specialty care advancements and leadership strategies for fostering innovation.

Samyukta Mullangi, MD, MBA, of Tennessee Oncology and Thyme Care, discusses the future of specialty value-based care and how attendees can apply what they learned at the Institute for Value-Based Medicine event on August 22.